• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of amjphAmerican Journal of Public Health Web SiteAmerican Public Health Association Web SiteSubmissionsSubscriptionsAbout Us
Am J Public Health. 1996 December; 86(12): 1717–1722.
PMCID: PMC1380723

From genes to public health: the applications of genetic technology in disease prevention. Genetics Working Group.

Abstract

OBJECTIVES: With advances in the Human Genome Project, the implications of genetic technology in disease prevention should be assessed. METHODS: The paradigm suggested in The Future of Public Health--assessment, policy development, and assurance--was used to examine the continuum from genetic technology to public health practice. RESULTS: First, important public health functions are to (1) assess the impact of genes and their interactions with modifiable disease risk factors on the health status of the population and (2) assess the impact and safety of genetic testing on the population. Second, given the many implications of genetic testing, the public health community should participate in policy development related to the timing and use of genetic testing in disease prevention. Third, whenever appropriate, the public health community needs to ensure the development of public health genetics programs (e.g. newborn screening) and evaluate the quality and effectiveness of the use of genetic testing in disease prevention. CONCLUSIONS: Although most current genetic tests are not ready for disease prevention, there is an important role for the public health community in translating genetic technology into disease prevention.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.5M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Watson JD. The human genome project: past, present, and future. Science. 1990 Apr 6;248(4951):44–49. [PubMed]
  • Jordan E. The Human Genome Project: where did it come from, where is it going? Am J Hum Genet. 1992 Jul;51(1):1–6. [PMC free article] [PubMed]
  • Hoffman EP. The Evolving Genome Project: current and future impact. Am J Hum Genet. 1994 Jan;54(1):129–136. [PMC free article] [PubMed]
  • Richards B, Skoletsky J, Shuber AP, Balfour R, Stern RC, Dorkin HL, Parad RB, Witt D, Klinger KW. Multiplex PCR amplification from the CFTR gene using DNA prepared from buccal brushes/swabs. Hum Mol Genet. 1993 Feb;2(2):159–163. [PubMed]
  • Garver KL, Garver B. The Human Genome Project and eugenic concerns. Am J Hum Genet. 1994 Jan;54(1):148–158. [PMC free article] [PubMed]
  • Schull WJ, Hanis CL. Genetics and public health in the 1990s. Annu Rev Public Health. 1990;11:105–125. [PubMed]
  • McKusick VA, Amberger JS. The morbid anatomy of the human genome: chromosomal location of mutations causing disease (update 1 December 1993). J Med Genet. 1994 Apr;31(4):265–279. [PMC free article] [PubMed]
  • Kalow W. The Pennsylvania State University College of Medicine 1990 Bernard B. Brodie Lecture. Pharmacogenetics: past and future. Life Sci. 1990;47(16):1385–1397. [PubMed]
  • King MC, Rowell S, Love SM. Inherited breast and ovarian cancer. What are the risks? What are the choices? JAMA. 1993 Apr 21;269(15):1975–1980. [PubMed]
  • Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994 Oct 7;266(5182):66–71. [PubMed]
  • Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, Bennett LM, Haugen-Strano A, Swensen J, Miki Y, et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science. 1994 Oct 7;266(5182):120–122. [PubMed]
  • Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet. 1995 Jan;56(1):265–271. [PMC free article] [PubMed]
  • Salmon RJ, Vilcoq JR. Cancer du sein après mammectomie sous-cutanée préventive. Presse Med. 1995 Sep 2;24(25):1167–1168. [PubMed]
  • Decker D. Prophylactic mastectomy for familial breast cancer. JAMA. 1993 May 26;269(20):2608–2609. [PubMed]
  • Kaback M, Lim-Steele J, Dabholkar D, Brown D, Levy N, Zeiger K. Tay-Sachs disease--carrier screening, prenatal diagnosis, and the molecular era. An international perspective, 1970 to 1993. The International TSD Data Collection Network. JAMA. 1993 Nov 17;270(19):2307–2315. [PubMed]
  • Shohat M, Legum C, Romem Y, Borochowitz Z, Bach G, Goldman B. Down syndrome prevention program in a population with an older maternal age. Obstet Gynecol. 1995 Mar;85(3):368–373. [PubMed]
  • Wald NJ, Densem JW, Smith D, Klee GG. Four-marker serum screening for Down's syndrome. Prenat Diagn. 1994 Aug;14(8):707–716. [PubMed]
  • Daly LE, Kirke PN, Molloy A, Weir DG, Scott JM. Folate levels and neural tube defects. Implications for prevention. JAMA. 1995 Dec 6;274(21):1698–1702. [PubMed]
  • Oakley GP, Jr, Erickson JD, Adams MJ., Jr Urgent need to increase folic acid consumption. JAMA. 1995 Dec 6;274(21):1717–1718. [PubMed]
  • Gaston MH, Verter JI, Woods G, Pegelow C, Kelleher J, Presbury G, Zarkowsky H, Vichinsky E, Iyer R, Lobel JS, et al. Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. N Engl J Med. 1986 Jun 19;314(25):1593–1599. [PubMed]
  • Schwaab R, Brackmann HH, Meyer C, Seehafer J, Kirchgesser M, Haack A, Olek K, Tuddenham EG, Oldenburg J. Haemophilia A: mutation type determines risk of inhibitor formation. Thromb Haemost. 1995 Dec;74(6):1402–1406. [PubMed]
  • Aly AM, Aledort LM, Lee TD, Hoyer LW. Histocompatibility antigen patterns in haemophilic patients with factor VIII antibodies. Br J Haematol. 1990 Oct;76(2):238–241. [PubMed]
  • Khoury MJ, Newill CA, Chase GA. Epidemiologic evaluation of screening for risk factors: application to genetic screening. Am J Public Health. 1985 Oct;75(10):1204–1208. [PMC free article] [PubMed]
  • Khoury MJ, Wagener DK. Epidemiological evaluation of the use of genetics to improve the predictive value of disease risk factors. Am J Hum Genet. 1995 Apr;56(4):835–844. [PMC free article] [PubMed]
  • Thunem Nancy Y, Lowry R Brian. Two of the authors reply. CMAJ. 1988 Aug 01;139(3):c194–197. [PMC free article]
  • Khoury MJ, Beaty TH. Applications of the case-control method in genetic epidemiology. Epidemiol Rev. 1994;16(1):134–150. [PubMed]
  • Wordsworth BP, Bell JI. The immunogenetics of rheumatoid arthritis. Springer Semin Immunopathol. 1992;14(1):59–78. [PubMed]
  • Weyand CM, Hicok KC, Conn DL, Goronzy JJ. The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis. Ann Intern Med. 1992 Nov 15;117(10):801–806. [PubMed]
  • Steere AC, Dwyer E, Winchester R. Association of chronic Lyme arthritis with HLA-DR4 and HLA-DR2 alleles. N Engl J Med. 1990 Jul 26;323(4):219–223. [PubMed]
  • Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993 Aug 13;261(5123):921–923. [PubMed]
  • Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 1993 Aug;43(8):1467–1472. [PubMed]
  • Tsai MS, Tangalos EG, Petersen RC, Smith GE, Schaid DJ, Kokmen E, Ivnik RJ, Thibodeau SN. Apolipoprotein E: risk factor for Alzheimer disease. Am J Hum Genet. 1994 Apr;54(4):643–649. [PMC free article] [PubMed]
  • Vineis P, Schulte PA. Scientific and ethical aspects of genetic screening of workers for cancer risk: the case of the N-acetyltransferase phenotype. J Clin Epidemiol. 1995 Feb;48(2):189–197. [PubMed]
  • Andrews LB, Jaeger AS. Confidentiality of genetic information in the workplace. Am J Law Med. 1991;17(1-2):75–108. [PubMed]
  • Billings P, Beckwith J. Genetic testing in the workplace: a view from the USA. Trends Genet. 1992 Jun;8(6):198–202. [PubMed]
  • Keverne EB. Molecular genetic approaches to understanding brain development and behaviour. Psychoneuroendocrinology. 1994;19(5-7):407–414. [PubMed]
  • Plomin R, Owen MJ, McGuffin P. The genetic basis of complex human behaviors. Science. 1994 Jun 17;264(5166):1733–1739. [PubMed]
  • Billings PR, Beckwith J, Alper JS. The genetic analysis of human behavior: a new era? Soc Sci Med. 1992 Aug;35(3):227–238. [PubMed]
  • Berkelman RL, Curran JW. Epidemiology of HIV infection and AIDS. Epidemiol Rev. 1989;11:222–228. [PubMed]
  • Leikin SL, Gallagher D, Kinney TR, Sloane D, Klug P, Rida W. Mortality in children and adolescents with sickle cell disease. Cooperative Study of Sickle Cell Disease. Pediatrics. 1989 Sep;84(3):500–508. [PubMed]

Articles from American Journal of Public Health are provided here courtesy of American Public Health Association

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • PubMed
    PubMed
    PubMed citations for these articles

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...